Jason Karlawish discusses the FDA’s decision to approve Alzheimer’s drug aducanumab in an op-ed for the journal Nature

In "Fix the Process that Led to Alzheimer’s Drug Fiasco," an op-ed for the journal Nature, PARC Research Associate Jason Karlawish advocates for reforms to the FDA's accelerated approval process.

Citation: 

• "Fix the Process that Led to Alzheimer’s Drug Fiasco," Nature, J Karlawish, May 31, 2022.